Professor Bo Dai: Targeting PSMA—How Novel Radioligand Therapies Are Reshaping the Treatment Landscape for Prostate Cancer
Editor’s Note: The 2025 Pujiang Prostate Cancer Academic Congress was held from June 27–28 in Shanghai, alongside the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer…
Professor Dingwei Ye: The Three Dimensions of Surgical Treatment for Prostate Cancer — Skill Advancement, Technological Innovation, and Conceptual Reform | 2025 CACA Integrated Prostate Oncology Conference
At the “CACA Integrated Prostate Oncology Conference” held from June 14–15, numerous Chinese experts and scholars gathered under the theme “Winning Through Integration in Cancer Control” to engage in academic discussions on the latest CACA prostate cancer guideline updates, recent research advances, and multidisciplinary team (MDT) evaluations of complex cases. Professor Dingwei Ye from Fudan University Shanghai Cancer Center delivered a keynote lecture titled “The Three Dimensions of Surgical Treatment for Prostate Cancer — Skill Advancement, Technological Innovation, and Conceptual Reform.” The following is a summary of his presentation.
Precision Therapy in mCRPC: Prof. Shouzhen Chen Highlights Molecular Subtyping Trends
At ASCO and EAU 2025, Professor Shouzhen Chen (Qilu Hospital, Shandong University) shared an in-depth overview of molecular subtyping in mCRPC. He emphasized established targets like HRR and MSI-H,…
2025 Advances from Dr. Husam Abu Jazar and the KHCC Team
In 2025, Dr. Husam Abu Jazar and colleagues at King Hussein Cancer Center published two impactful studies that could shape transplant care moving forward. The first study analyzed outcomes from…
EBMT 2025: Opening Ceremony Celebrates Legacy, Innovation, and a Unified Vision for the Future of Transplantation
Florence, Italy — March 30, 2025 – The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) commenced in Florence with a compelling and multifaceted opening ceremony that captured the essence of what the EBMT represents. Far beyond a traditional welcome, the evening unfolded as a rich tapestry of scientific achievement, heartfelt remembrance, and forward-looking vision.
Redefining Infection Prevention: Dr. Doris Ponce on the Clinical Promise of SER-155 and the Future of Microbiome Therapeutics
Live biotherapeutic products are rapidly changing the landscape of infection prevention, particularly in immunocompromised patients. Among these, SER-155, a multi-strain oral therapy, has demonstrated compelling clinical results. In a recent trial, the incidence of bloodstream infections (BSIs) dropped sharply in the SER-155 group compared to placebo (10% vs. 42.9%). This finding signals a potential breakthrough in both infection control and microbiome modulation. In this interview, Dr. Doris Ponce discusses the mechanisms behind SER-155, its implications for antimicrobial resistance, and its future applications beyond transplant medicine. Her responses provide an in-depth look at how microbiome science is poised to transform not only prevention but also personalized therapeutic strategies in clinical care.